Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week
MWN-AI** Summary
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, is set to participate in the "Voice of the Patient" event during Arizona Tech Week on April 9, 2026, in Tucson, Arizona. This event, organized by the Arizona Bioindustry Association (AZBio), focuses on emphasizing patient perspectives in healthcare innovation and aims to bridge the gap between patients, clinicians, and healthcare leaders.
Dr. Francisco Arabia, an expert in heart transplantation and mechanical circulatory support, will represent SynCardia at the event. With extensive experience in performing SynCardia Total Artificial Heart procedures, Dr. Arabia is well-positioned to share valuable insights on the implications of this advanced treatment. He will be joined by Amanda Vaji, Manager of the Mechanical Circulatory Support Program at Banner University Medical Center Phoenix, along with a patient who will provide a personal account of their experience with SynCardia therapy.
Patrick NJ Schnegelsberg, CEO of Picard Medical and SynCardia, emphasized the importance of integrating patient experiences into discussions about healthcare innovation, stating, “Advanced heart failure treatment is not only about technology. It is about patients, families, recovery, and quality of life.”
The "Voice of the Patient" event will gather various stakeholders to discuss the real-world impact of innovative therapies across multiple diseases, further supporting the ongoing conversation on improving patient care through technological advancements.
With over 2,100 implants worldwide, the SynCardia Total Artificial Heart is recognized as the first and only artificial heart approved by both the U.S. FDA and Health Canada, making it a pivotal technology in the treatment of end-stage heart failure. For more information on Picard Medical and SynCardia, visit their official website or review their SEC filings.
MWN-AI** Analysis
**Market Analysis and Investment Advice on Picard Medical/SynCardia**
As Picard Medical, Inc. (NYSE American: PMI) gears up for its participation in the "Voice of the Patient" event on April 9, 2026, during AZ Tech Week, several key factors merit consideration for investors looking at the company's stock as part of their portfolio. The event serves as a platform for advancing discussions around the role of patient perspectives in healthcare innovation, particularly in the realm of advanced heart failure treatments, a core competency for SynCardia.
Participation in the event underscores Picard Medical’s commitment to elevating patient care and innovation. The presence of industry leaders such as Dr. Francisco Arabia and Amanda Vaji highlights the company's established network within the healthcare community and signals confidence in its flagship product, the SynCardia Total Artificial Heart. The growing body of clinical evidence supporting SynCardia's technology—backed by over 2,100 implants worldwide—positions the company favorably in a market that is increasingly focused on patient outcomes.
Moreover, the event aligns with broader healthcare trends emphasizing individualized treatment and continuous patient engagement. As healthcare systems evolve, companies like Picard Medical that prioritize patient voices may see enhanced adoption of their technologies, potentially leading to increased revenues.
From an investment perspective, PMI could be considered an attractive opportunity due to its unique position in a niche but expanding market. However, potential investors should remain mindful of inherent risks, including regulatory challenges and competitive pressures from newer technologies.
In summary, with its strong foundation in innovative heart failure solutions and a commitment to understanding patient needs, Picard Medical warrants attention in the current market landscape. Investors should watch for updates from the AZ Tech Week event, as stakeholder engagement could influence market perceptions and share price trajectory in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TUCSON, Ariz., April 01, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the “Voice of the Patient” event during AZ Tech Week, a program focused on elevating patient perspectives in healthcare innovation hosted by the Arizona Bioindustry Association (“AZBio”), the state’s leading organization representing biotechnology and medical device companies. The event will bring together patients, clinicians, and healthcare leaders to discuss the real-world impact of advanced medical technologies.
Dr. Francisco Arabia, an internationally recognized leader in heart transplantation and mechanical circulatory support, will represent the SynCardia Total Artificial Heart perspective. Dr. Arabia has participated in over 200 SynCardia Total Artificial Heart procedures as an implanting surgeon, proctor, or assisting surgeon at leading transplant and advanced heart failure programs, including Banner University Medical Center Phoenix, the Mayo Clinic in Arizona, Cedars Sinai Medical Center in Los Angeles, and the University of Arizona, among others. He will be joined by Amanda Vaji, Manager of the Mechanical Circulatory Support Program at Banner University Medical Center Phoenix, as well as a patient who will share firsthand experience with SynCardia therapy and recovery from advanced heart failure.
The broader program will feature patients, clinicians, and healthcare leaders discussing the impact of innovative therapies across a range of diseases.
The event will take place on Thursday, April 9, 2026, from 1:00 PM to 4:00 PM at the University of Arizona Health Sciences Innovation Forum in Tucson, Arizona. Registration is available at: https://www.azbio.org/events/voice-of-the-patient-az-tech-week/.
“Advanced heart failure treatment is not only about technology. It is about patients, families, recovery, and quality of life,” said Patrick NJ Schnegelsberg, CEO of the Company and of SynCardia. “We are pleased to participate in this event and support a broader conversation that brings patient experience directly into discussions about innovation and care.”
About Arizona Tech Week
Arizona Tech Week is a statewide innovation conference that brings together founders, investors, researchers, and industry leaders through a series of events hosted across Arizona. The life sciences programming is supported by AZBio. As part of this program, the “Voice of the Patient” event highlights patient perspectives across a range of diseases and medical technologies and brings together clinicians, innovators, and patients to discuss the real-world impact of healthcare innovation. The Company / SynCardia, as member of AZBio, are proud to support the “Voice of the Patient “event as part of AZ Tech Week.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
How does Picard Medical Inc. PMI plan to leverage insights from the “Voice of the Patient” event to enhance the design and functionality of its SynCardia Total Artificial Heart?
What impact does Picard Medical Inc. PMI anticipate from the participation of Dr. Francisco Arabia at AZ Tech Week on the future of heart transplantation and mechanical circulatory support?
In what ways will the experiences shared by patients at the “Voice of the Patient” event influence Picard Medical Inc. PMI’s future innovations in advanced heart failure treatment?
How does Picard Medical Inc. PMI aim to address challenges in the treatment of advanced heart failure based on feedback received during events like AZ Tech Week?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
16.83% G/L:
$0.5025 Last:
22,005,914 Volume:
$0.462 Open:
